Reuters2022-10-25
Quarterly operating income at Swiss drugmaker Novartis slipped as competition weighed on prescriptions of multiple sclerosis drug Gilenya.
For Novartis, which reports results in dollars, a strong U.S. currency was also a drag on the value of sales generated outside the United States.
Third-quarter core operating income declined 4% to $4.28 billion, slightly below the average analyst consensus of $4.30 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial